Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor.
Zelminemab (10 mg/kg; i.v.; once) reduces nociceptive neu-ronal activity in the TCC[2].
References:
[1]. Eloisa Rubio-Beltrán, et al. PACAP38 and PAC1 receptor blockade: a new target for headache J Headache Pain. 2018 Aug 7;19(1):64.
[2]. Hoffmann J, et al. PAC-1 receptor antibody modulates nociceptive trigeminal activity in rat. Cephalalgia. 2016;36(1S):141–141.
















